Semaglutide has been used since 2021 under the brand name, Wegovy, to treat patients with a BMI of 30 or more and patients with a BMI of 27 or more with co-existing weight-related medical problems, including high blood pressure, high cholesterol, obstructive sleep apnea, or heart/vascular disease.[4] As I mentioned above, semaglutide is circulated throughout the body and takes roughly one week to be eliminated through the urine and feces.[5] During its circulation, it interacts with several organs that work together to contribute to weight loss
Im here to answer any questions you have, so please dont hesitate to reach out
Biomarkers and Metabolic Context in Decision-Making Your metabolic biomarkersincluding fasting glucose, insulin levels, lipid panel, and liver functionprovide a baseline picture of how your body responds to insulin and glucose regulation
In the face of these habitual changes, what does this mean for the QSR industry as a whole